Anmeldung erfolgt in Kürze...
Details werden geladen...
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers | The Manila Times
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer
Ähnliche Seiten
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | The Manila Times
https://www.manilatimes.net/2026/05/11/tmt-newswire/globenewswire/dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights/2340634TeraWulf Reports First Quarter 2026 Results | The Manila Times
https://www.manilatimes.net/2026/05/08/tmt-newswire/globenewswire/terawulf-reports-first-quarter-2026-results/2339406Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | The Manila Times
https://www.manilatimes.net/2026/04/30/tmt-newswire/globenewswire/cartesian-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update/2332597BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | The Manila Times
https://www.manilatimes.net/2026/05/15/tmt-newswire/globenewswire/bioxcel-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results/2344827Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | The Manila Times
https://www.manilatimes.net/2026/05/12/tmt-newswire/globenewswire/tenax-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update/2341592